The Benefits of Nicotine: Why Palantir and Silicon Valley Are Betting on Nicotine Pouches

Walk into Palantir's Washington, D.C. office and you'll find something unexpected next to the cold brew and sparkling water. Nicotine pouch vending machines. Branded machines from startups Lucy and Sesh sit in the break area, free for any employee over 21. And Palantir isn't alone. A growing number of tech companies are stocking nicotine pouches as a workplace perk, treating them the same way they'd treat free kombucha or standing desks.

This isn't some fringe experiment. It's a signal that Silicon Valley has caught on to something researchers have studied for decades: the benefits of nicotine for cognitive performance. The question is whether the science backs up the hype, and what it means for the millions of people now reaching for pouches instead of cigarettes.

What's Happening at Palantir and Other Tech Companies

Palantir, the data analytics giant valued at over $50 billion, started offering free nicotine pouches in its offices as part of a broader push toward biohacking culture. The company partnered with two nicotine startups, Lucy and Sesh, to install branded vending machines. Employees and guests over 21 can grab pouches whenever they want.

The reasoning is straightforward. Palantir's work involves long hours of deep analytical thinking. If a substance can sharpen focus for even 20 or 30 minutes, that adds up over an 80-hour work week. The company sees nicotine pouches the same way it sees free meals and gym memberships: tools to keep employees operating at their best.

Palantir is the most visible example, but the trend runs deeper. Multiple tech startups have started offering nicotine pouches as perks. The biohacking community in Silicon Valley has embraced nicotine as a cognitive enhancer for years. What's changed is that companies are now making it official policy rather than leaving it to individual choice.

The Benefits of Nicotine for the Brain: What the Science Actually Says

Is nicotine good for your brain? The short answer is: it depends on who you are and how you use it.

Nicotine binds to acetylcholine receptors in the brain. These receptors play a central role in attention, memory formation, and learning. When nicotine hits them, the result is a short burst of enhanced cognitive function. Your working memory gets a boost. You can sustain attention longer. Reaction times speed up.

This isn't marketing spin. Peer-reviewed studies have confirmed these positive effects of nicotine on cognition. Research published in journals like Psychopharmacology and Neuropsychologia has repeatedly shown that nicotine improves attention and memory in controlled experiments. A 2023 meta-analysis looking at dozens of studies found consistent evidence that nicotine enhances fine motor skills, attention accuracy, and response time.

There's also the dopamine angle. Nicotine triggers dopamine release in the brain's reward circuit, which creates a feeling of alertness and mild euphoria. That's the "buzz" pouch users describe, and it's why many people report feeling more motivated and locked in after using a pouch.

Is Nicotine a Nootropic?

The nootropic community has been calling nicotine a cognitive enhancer for years. A nootropic is any substance that improves mental performance, and by that definition, nicotine qualifies. It sharpens focus, speeds up processing, and can improve short-term memory recall.

But there's an important caveat. Dipa Kamdar, a senior lecturer in Pharmacy Practice at Kingston University, has pointed out that people who already have healthy brain function are performing close to their ceiling. The biggest cognitive gains from nicotine tend to show up in people who have some existing cognitive deficit or who are sleep-deprived, stressed, or fatigued.

For a tech worker pulling a 14-hour day? That describes most of them by hour 10. Which is exactly when a nicotine pouch becomes most effective.

Why Nicotine Pouches Specifically?

There are many ways to consume nicotine. Cigarettes, vapes, patches, gum, lozenges. So why are tech companies specifically choosing pouches?

Pouches are small, discreet, and smokeless. You tuck one between your gum and lip, and it slowly releases nicotine over 20 to 45 minutes. No smoke, no vapor, no smell. You can use one during a meeting, on a video call, or at your desk without anyone knowing.

They're also considered the safest commercially available nicotine product outside of pharmaceutical options like patches. The Wall Street Journal reported that nicotine pouches are considered the "least harmful nicotine option" because they don't involve combustion, which is responsible for almost all of the cancer-causing chemicals in cigarettes. No tar, no carbon monoxide, no particulate matter entering your lungs.

The FDA has authorized 26 nicotine pouch products to date. Twenty of those are ZYN products from Swedish Match (owned by Philip Morris International), and six are on! PLUS products from Helix Innovations. These authorizations came after extensive scientific review and represent the FDA's assessment that these products are "appropriate for the protection of public health."

The Tucker Carlson Factor and the Wellness Crossover

The nicotine pouch trend hasn't stayed confined to tech offices. It's crossed into the broader wellness and media space in a big way.

Tucker Carlson, the conservative media personality, launched his own nicotine pouch brand called ALP in collaboration with Turning Point Brands. He's described nicotine as a "life-enhancing" compound. Other media figures and influencers have followed, advocating nicotine use as a tool for improved focus, appetite control, and more.

That appetite control angle is particularly interesting. Nicotine appears to influence the parts of the brain that control hunger and makes the body burn more energy. The effects are similar to GLP-1 receptor agonists like semaglutide (the active ingredient in Ozempic and Wegovy), which have become the most talked-about weight loss drugs in recent memory. Some researchers have noted the overlap between nicotine's mechanism and GLP-1 drugs, though the comparison is far from perfect.

Fitness influencers have picked up on this. Nicotine pouches are showing up in gym bags and pre-workout routines. The combination of appetite suppression, enhanced focus, and a slight metabolic boost makes them appealing to people who are already optimizing every other variable in their health.

The Market Is Exploding

The numbers tell the story better than any trend piece can.

ZYN alone posted $3.24 billion in sales last year. That's more than two-thirds of the entire nicotine pouch market in the United States. Total monthly nicotine pouch sales in the US increased by roughly 250% between January 2023 and August 2025, according to CDC data.

The global nicotine pouch market was valued at $3.13 billion in 2024. Analysts project it will hit $4.27 billion in 2025 and could reach $50.82 billion by 2033, growing at a compound annual rate of 36.3%. That makes nicotine pouches one of the fastest-growing consumer product categories in the world.

Fewer than 1% of US adults currently use nicotine pouches. But the growth curve is steep, and the Palantir-style office adoption could accelerate it further. When a product goes from "thing you buy at a gas station" to "free perk at a $50 billion tech company," the social dynamics shift fast.

The FDA Is Moving Toward a Lower-Risk Label

Here's where things get really interesting for nicotine pouch users.

Philip Morris International has applied for permission to market ZYN as a "modified risk tobacco product." That's FDA language meaning the company wants to tell consumers, on the label and in advertising, that switching from cigarettes to ZYN lowers the risk of lung cancer, heart disease, stroke, and mouth cancer.

In January 2026, the FDA held a Tobacco Products Scientific Advisory Committee meeting to review the application. During a preliminary review, the FDA said the claim that ZYN lowers the risk of smoking-related diseases appears to be "scientifically accurate." That's a huge deal. If approved, ZYN would become the first nicotine pouch allowed to carry a reduced-risk marketing claim.

The FDA has already authorized 20 ZYN products through the premarket tobacco product application pathway, meaning the agency has reviewed the science and determined that marketing these products is "appropriate for the protection of public health." The modified risk designation would go a step further, essentially letting ZYN tell smokers: "We're a better option."

What About the Risks?

No honest discussion of nicotine's benefits can skip the risks. Nicotine is addictive. That's not debatable. Regular use creates dependence, and quitting can involve withdrawal symptoms like irritability, difficulty concentrating, and cravings.

Nicotine also raises blood pressure and heart rate temporarily. Long-term cardiovascular effects of nicotine pouch use specifically haven't been studied over decades the way cigarettes have. The products are too new for that data to exist.

There's also a concern about people who have never smoked picking up pouches. The positive effects of nicotine on cognition are real, but they come packaged with a substance that your brain will want more of. Starting a nicotine habit from scratch is a different risk calculation than switching from cigarettes to pouches.

That said, the FDA's own analysis has repeatedly distinguished between nicotine and tobacco combustion products. Nicotine itself doesn't cause cancer. The overwhelming majority of smoking-related disease comes from the thousands of chemicals produced by burning tobacco. Nicotine pouches eliminate combustion entirely.

How Smokers Are Using Pouches to Quit

While tech companies focus on the cognitive benefits, another story is playing out. Smokers are using nicotine pouches as a stepping stone away from cigarettes.

Research from Rutgers University published in JAMA Network Open found that people were nearly four times more likely to use nicotine pouches daily if they had recently quit smoking. Among current smokers, those using nicotine pouches had significantly higher odds of intending to quit within six months (78% higher) and within 30 days (109% higher).

Only about 2.5% of US adults use nicotine pouches right now. But among people who attempted to quit smoking in the past year and relapsed, 5.2% reported using pouches to help with their cessation efforts. These numbers are small but growing quickly.

Nicotine pouches can't be marketed as smoking cessation aids. That regulatory category belongs to pharmaceutical products like patches and gum that have gone through clinical trials for that specific purpose. But the real-world data suggests that many users are treating them that way, regardless of what the label says.

The Bigger Picture: From Stigma to Silicon Valley Perk

Ten years ago, if you told someone that a $50 billion tech company would stock nicotine products in its office, they would have laughed. Nicotine was smoking. Smoking was bad. End of discussion.

What's changed is that the conversation has matured. Scientists, regulators, and now companies are separating nicotine the molecule from tobacco the delivery system. Nicotine has real cognitive benefits. It's addictive, yes. But when delivered through a pouch instead of a cigarette, the harm profile drops dramatically.

The FDA authorizing 26 nicotine pouch products and seriously considering a reduced-risk label for ZYN is an institutional acknowledgment of this distinction. Palantir stocking pouches in its offices is a corporate one. The market tripling in two years is a consumer one.

Whether you think of nicotine pouches as a nootropic, a smoking alternative, or just a cleaner way to get a buzz, the trajectory is clear. This category is growing, the science is catching up to the hype, and the stigma is fading.

Frequently Asked Questions

Is nicotine good for your brain?

Nicotine activates acetylcholine receptors involved in attention, memory, and learning. Studies show it can improve focus, reaction time, and working memory. The effects are most pronounced in people who are fatigued, sleep-deprived, or have existing cognitive difficulties. Healthy individuals performing at baseline see smaller improvements.

Is nicotine a nootropic?

By the standard definition of a nootropic (a substance that enhances cognitive function), yes. Nicotine improves attention, memory recall, and processing speed. It's one of the most studied cognitive enhancers. The tradeoff is that it's also addictive, which separates it from most supplements marketed as nootropics.

Why is Palantir offering free nicotine pouches to employees?

Palantir partnered with nicotine startups Lucy and Sesh to install branded vending machines in its offices. The company views nicotine pouches as a productivity tool, similar to free meals or gym access. Employees over 21 can use them freely. It's part of a broader biohacking culture that has taken hold in Silicon Valley.

What are the positive effects of nicotine pouches?

Nicotine pouches deliver nicotine without combustion, tar, or smoke. Users report improved focus, alertness, and mood. Because they don't involve burning tobacco, they avoid the cancer-causing chemicals found in cigarettes. The FDA has authorized 26 nicotine pouch products after scientific review.

Are nicotine pouches FDA approved?

The FDA has authorized 26 nicotine pouch products (20 ZYN and 6 on! PLUS) through the premarket tobacco product application pathway. "Authorization" means the FDA determined marketing these products is appropriate for public health. It's different from "approval," which is the term used for pharmaceutical drugs.

Can nicotine pouches help you quit smoking?

Nicotine pouches aren't officially marketed as cessation aids. But research from Rutgers University found that people who recently quit smoking were nearly four times more likely to use pouches daily. Smokers who used pouches were also significantly more likely to intend to quit within six months. Many smokers appear to be using them as an informal quit tool.

What does nicotine do to the brain?

Nicotine binds to acetylcholine receptors and triggers dopamine release in the brain's reward pathway. This creates a short-term boost in attention, working memory, and processing speed, along with feelings of alertness and mild euphoria. The effects typically last 20 to 45 minutes with a pouch.

Do nicotine pouches suppress appetite?

Yes. Nicotine influences brain regions that control hunger and increases the body's energy expenditure. Some researchers have noted similarities between nicotine's appetite-suppressing mechanism and GLP-1 receptor agonists like semaglutide (Ozempic). Fitness influencers have started incorporating pouches partly for this reason.

How big is the nicotine pouch market?

The global market was valued at $3.13 billion in 2024 and is projected to reach $50.82 billion by 2033, growing at 36.3% annually. ZYN alone posted $3.24 billion in US sales. Total monthly nicotine pouch sales in the US increased by roughly 250% between January 2023 and August 2025.

Are nicotine pouches safer than cigarettes?

The FDA's preliminary review found that the claim ZYN lowers the risk of smoking-related diseases appears to be "scientifically accurate." Nicotine pouches eliminate combustion, which is responsible for the overwhelming majority of cigarette-related disease. They contain no tar, no carbon monoxide, and no particulate matter. Philip Morris is seeking FDA authorization to market ZYN with a reduced-risk label.

Sources and Further Reading